Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.38 |
| ▸ | RARB | P10826 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | MPL | P40238 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17355578 | 0.94 | RARB (0.41) | GRM2S1PR1S1PR3RARBALOX5AP | |
| SCHEMBL17355545 | 0.93 | GRM2 (0.37) | GRM2S1PR1S1PR3RARBALOX5AP | |
| SCHEMBL17355459 | 0.93 | RARB (0.45) | GRM2S1PR1S1PR3RARBALOX5AP | |
| SCHEMBL17355492 | 0.93 | GRM2 (0.38) | GRM2S1PR1S1PR3RARBALOX5AP | |
| SCHEMBL17355470 | 0.92 | S1PR1 (0.34) | GRM2S1PR1S1PR3RARBKIF11 | |
| SCHEMBL17369503 | 0.92 | RARB (0.44) | GRM2S1PR1S1PR3RARBALOX5AP | |
| SCHEMBL17355580 | 0.92 | GRM2 (0.40) | GRM2S1PR1S1PR3RARBALOX5AP | |
| SCHEMBL17378023 | 0.91 | GRM2 (0.35) | GRM2S1PR1S1PR3RARBKIF11 | |
| SCHEMBL17355460 | 0.91 | KIF11 (0.36) | GRM2S1PR1S1PR3RARBKIF11 | |
| SCHEMBL17377955 | 0.91 | KIF11 (0.35) | GRM2S1PR1S1PR3RARBKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9657229-B2 | Liquid crystal compound having difluoromethyleneoxy, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2017-05-23 | — | — | US | disclosed |
| US-9657229-B2 | Liquid crystal compound having difluoromethyleneoxy, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2017-05-23 | — | — | US | disclosed |
| US-20150376502-A1 | LIQUID CRYSTAL COMPOUND HAVING DIFLUOROMETHYLENEOXY, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2015-12-31 | — | — | US | disclosed |
| US-20150376502-A1 | LIQUID CRYSTAL COMPOUND HAVING DIFLUOROMETHYLENEOXY, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2015-12-31 | — | — | US | disclosed |
| EP-2957554-A1 | LIQUID-CRYSTALLINE COMPOUND HAVING DIFLUOROMETHYLENEOXY GROUP, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC Corporation (JP) | 2015-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376502-A1 | LIQUID CRYSTAL COMPOUND HAVING DIFLUOROMETHYLENEOXY, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | C1S, CPNE4, PIEZO1 | GRM2 3326/4885S1PR1 1941/4885S1PR3 1514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.